NGC is the National Guideline Clearinghouse.
primary and specialist healthcare provider in the evaluation and management of gastroesophageal reflux ( GER) and gastroesophageal reflux disease ( GERD) in the pediatric age group infants, children and adolescents. ... They were written by a joint
37 White, 3 not given Moderate to-severe asthma Patients presented to urban, pediatric ED Pulmonary index ( PI) score of > 8 out of 15; mean 10.2 at entry Beta2-agonist, ... Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma:
July 2007 2 Evidence Table 19. Managing Exacerbations: Magnesium Sulfate Study Population Citation ( Sponsor) Study Design Study N ( Number Evaluable) Population Characteristics Asthma Severity at Baseline ( if reported) Magnesium by Nebulizer
pubmed.gov - 3/1/08
National Heart, Lung, and Blood Institute clinical practice guidelines strongly recommend that health professionals educate children with asthma and their caregivers about self-management. We conducted a meta-analysis to estimate the effects of pediatric asthma education on hospitalizations, emergency department visits, and urgent physician visits for asthma.|Inclusion criteria included enrollment of children aged 2 to 17 years with a clinical diagnosis of asthma who resided in the United States. Pooled standardized mean differences and pooled odds ratios were calculated. Random-effects models were estimated for all outcomes assessed.|Of the 208 studies identified and screened, 37 met the inclusion criteria. Twenty-seven compared educational interventions to usual care, and 10 compared different interventions. Among studies that compared asthma education to usual care, education was associated with statistically significant decreases in mean hospitalizations and mean emergency
Commercial versus home-made spacers in delivering bronchodilator therapy for acute therapy in children.
pubmed.gov - 1/1/08
Strong evidence supports the use of metered-dose inhalers combined with a spacer for delivering rapid-acting inhaled beta-2 agonists in the treatment of acute exacerbations of asthma in children. The high cost and lack of availability of commercially produced spacers however, have limited their use in developing countries.|The aim of this review was to compare the response to inhaled beta-2 agonists delivered through metered-dose inhaler using home-made spacers, to the use of commercially produced spacers, in children with acute exacerbations of wheezing or asthma.|We searched the Cochrane Central Register of Controlled Trials (CENTRAL) The Cochrane Library Issue 3, 2007,(up to August 2007) MEDLINE , EMBASE, CINHAL, LILACS and reference lists of included studies. We contacted authors and known experts in the field, and approached pharmaceutical companies that manufacture inhalation spacers to identify additional published or unpublished data. No language restrictions were
pubmed.gov - 1/1/08
19099041 2008 12 22 2009 02 19 2009 11 18 1934-1997 10 10 Medscape J Med 247 Pediatrics and Pediatric Allergology, Turku Allergy Center, Turku, Finland. ... 2007 Aug; 120( 2): 381-7 17560637 Clin Ther. 2007 Feb; 29( 2): 342-51 17472826 Ann Allergy Asthma
pubmed.gov - 12/1/07
There have been a number of guidelines for asthma treatment published throughout the world. However, childhood asthma guidelines must be developed in consideration of the background of the individual countries. The second version of the Japanese Pediatric Guideline for the Treatment and Management of Bronchial Asthma 2002 (JPGL 2002) was published by the Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI) in November 2002, and was popular among Japanese physicians. After the publication of the JPGL, the incidence of pediatric asthma deaths decreased in Japan. In JPGL 2005 the recommendations were re-edited based on Global Initiative for Asthma (GINA) and the JPGL 2002. In comparison to the GINA guidelines, the JPGL 2005 include a classification system of asthma severity, recommendations for long-term management organized by age, a special mention of infantile asthma, and an emphasis on prevention and early intervention.
Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations.
pubmed.gov - 2/1/07
Combination therapy with long-acting beta-agonists (LABAs)/inhaled corticosteroids (ICSs) has become established as effective maintenance treatment for asthma.|To compare and contrast the efficacy and safety of LABAs/ICSs against different maintenance ICS strategies in adults with asthma.|Cochrane systematic reviews of randomized controlled trials (to April 2004) were identified that compared the addition of LABA to ICS against 3 inhaled corticosteroid strategies: (1) a similar dose (n = 4312 subjects), (2) a higher dose (n = 4951), and (3) a similar dose in steroid-naive subjects (n = 968). The outcomes evaluated were asthma exacerbations, asthma control, and adverse effects. Pediatric studies were excluded.|The addition of LABA to ICSs significantly reduced the risk of exacerbations compared with a similar ICS dose, number needed to treat = 18. The effects of LABA/ICSs on exacerbations compared with the other maintenance inhaled corticosteroid strategies were not statistically